The interplay between emerging human coronavirus infections and autophagy. 2021

Zhenyu Zhao, and Kefeng Lu, and Binli Mao, and Shi Liu, and Mirko Trilling, and Ailong Huang, and Mengji Lu, and Yong Lin
Key Laboratory of Molecular Biology of Infectious Diseases (Chinese Ministry of Education), Department of Infectious Diseases, The Second Affiliated Hospital, Institute for Viral Hepatitis, Chongqing Medical University, Chongqing, People's Republic of China.

ABSTRACT Following outbreaks of severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2002 and 2012, respectively, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the third highly pathogenic emerging human coronavirus (hCoV). SARS-CoV-2 is currently causing the global coronavirus disease 2019 (COVID-19) pandemic. CoV infections in target cells may stimulate the formation of numerous double-membrane autophagosomes and induce autophagy. Several studies provided evidence that hCoV infections are closely related to various cellular aspects associated with autophagy. Autophagy may even promote hCoV infection and replication. However, so far it is unclear how hCoV infections induce autophagy and whether the autophagic machinery is necessary for viral propagation. Here, we summarize the most recent advances concerning the mutual interplay between the autophagic machinery and the three emerging hCoVs, SARS-CoV, MERS-CoV, and SARS-CoV-2 and the model system mouse hepatitis virus. We also discuss the applicability of approved and well-tolerated drugs targeting autophagy as a potential treatment against COVID-19.

UI MeSH Term Description Entries
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006517 Murine hepatitis virus A species of the CORONAVIRUS genus causing hepatitis in mice. Four strains have been identified as MHV 1, MHV 2, MHV 3, and MHV 4 (also known as MHV-JHM, which is neurotropic and causes disseminated encephalomyelitis with demyelination as well as focal liver necrosis). Gastroenteritis Virus, Murine,Hepatitis Virus, Mouse,Mouse Hepatitis Virus,Murine Gastroenteritis Virus,MHV-JHM,Murine coronavirus,Gastroenteritis Viruses, Murine,Hepatitis Viruses, Mouse,Mouse Hepatitis Viruses,Murine Gastroenteritis Viruses,Murine coronaviruses,Murine hepatitis viruses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071182 Autophagosomes Large spherical double-layered structures which function in AUTOPHAGY to engulf intracellular components such as ORGANELLES or pathogens. Their outer membrane then fuses with the LYSOSOME (forming the AUTOLYSOSOME) and the inner membrane and contents are digested by lysosomal HYDROLASES. Phagophores,Autophagosome,Phagophore
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000093485 COVID-19 Drug Treatment The use of DRUGS to treat COVID19 or its symptoms. COVID-19 Drug Therapy,COVID19 Drug Therapy,COVID19 Drug Treatment,Coronavirus Disease 2019 Drug Treatment,Coronavirus Disease-19 Drug Treatment,COVID 19 Drug Therapy,COVID 19 Drug Treatment,COVID-19 Drug Therapies,COVID19 Drug Therapies,COVID19 Drug Treatments,Coronavirus Disease 19 Drug Treatment,Drug Therapy, COVID-19,Drug Therapy, COVID19,Therapy, COVID-19 Drug,Therapy, COVID19 Drug,Treatment, COVID-19 Drug
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001343 Autophagy The segregation and degradation of various cytoplasmic constituents via engulfment by MULTIVESICULAR BODIES; VACUOLES; or AUTOPHAGOSOMES and their digestion by LYSOSOMES. It plays an important role in BIOLOGICAL METAMORPHOSIS and in the removal of bone by OSTEOCLASTS. Defective autophagy is associated with various diseases, including NEURODEGENERATIVE DISEASES and cancer. Autophagocytosis,ER-Phagy,Lipophagy,Nucleophagy,Reticulophagy,Ribophagy,Autophagy, Cellular,Cellular Autophagy,ER Phagy
D016679 Genome, Viral The complete genetic complement contained in a DNA or RNA molecule in a virus. Viral Genome,Genomes, Viral,Viral Genomes

Related Publications

Zhenyu Zhao, and Kefeng Lu, and Binli Mao, and Shi Liu, and Mirko Trilling, and Ailong Huang, and Mengji Lu, and Yong Lin
August 2021, Cells,
Zhenyu Zhao, and Kefeng Lu, and Binli Mao, and Shi Liu, and Mirko Trilling, and Ailong Huang, and Mengji Lu, and Yong Lin
October 2013, Diabetes & metabolism journal,
Zhenyu Zhao, and Kefeng Lu, and Binli Mao, and Shi Liu, and Mirko Trilling, and Ailong Huang, and Mengji Lu, and Yong Lin
December 2020, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS),
Zhenyu Zhao, and Kefeng Lu, and Binli Mao, and Shi Liu, and Mirko Trilling, and Ailong Huang, and Mengji Lu, and Yong Lin
January 2019, Frontiers in cellular and infection microbiology,
Zhenyu Zhao, and Kefeng Lu, and Binli Mao, and Shi Liu, and Mirko Trilling, and Ailong Huang, and Mengji Lu, and Yong Lin
December 2020, The American journal of the medical sciences,
Zhenyu Zhao, and Kefeng Lu, and Binli Mao, and Shi Liu, and Mirko Trilling, and Ailong Huang, and Mengji Lu, and Yong Lin
March 2023, Antioxidants & redox signaling,
Zhenyu Zhao, and Kefeng Lu, and Binli Mao, and Shi Liu, and Mirko Trilling, and Ailong Huang, and Mengji Lu, and Yong Lin
January 2020, Frontiers in cell and developmental biology,
Zhenyu Zhao, and Kefeng Lu, and Binli Mao, and Shi Liu, and Mirko Trilling, and Ailong Huang, and Mengji Lu, and Yong Lin
January 2020, Frontiers in immunology,
Zhenyu Zhao, and Kefeng Lu, and Binli Mao, and Shi Liu, and Mirko Trilling, and Ailong Huang, and Mengji Lu, and Yong Lin
December 2020, Emerging microbes & infections,
Zhenyu Zhao, and Kefeng Lu, and Binli Mao, and Shi Liu, and Mirko Trilling, and Ailong Huang, and Mengji Lu, and Yong Lin
January 2012, Frontiers in oncology,
Copied contents to your clipboard!